
Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.
Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.
The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.
The CDC stressed that antimicrobial stewardship remains a major public health concern.
The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.
Investigators in Tennessee detailed associations between seasonal increases in sporadic pediatric cases of norovirus gastroenteritis and reported norovirus outbreaks among older populations.
Regimen reduces mortality and recovery time in patients severely ill with pneumonia caused by the virus.
At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.
Review of data in trial registries shows they specifically excluded this group from studies involving therapies.
Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.
Covaxx CEO Mei Mei Hu has seen vaccines from development all the way through to government approval. She offers her unique perspective into vaccine creation and an update on her company’s COVID-19 vaccine.
Modulating gut microbiota could have therapeutic benefits for people living with HIV, according to a recent study that found HIV infection in women was associated with altered gut microbiota and distinct plasma metabolite profile.
New research finds the rate of psychological distress among US adults remained more than 3 times higher than normal in the early months of the pandemic.
Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development.
UV light-emitting diodes are an emerging technology and a UV source for pathogen inactivation.
In a mature market of agents, the investigational therapy, ibrexafungerp, from Scynexis is looking at a few antifungal indications with a potential FDA approval in 2021.
This non-prescription test allows users to perform and get results themselves without a medical provider or laboratory needed.
Data from three ongoing clinical studies were included in the EUA request.
A new study in JAMA recently evaluated and assessed the racial and ethnic disparities in hospitalizations and mortality across COVID-19 patients within New York City.
Investigators are calling for routine use of these tests for patients admitted with acute respiratory symptoms during the influenza season.
As Covid-19 infections soar across the U.S., states are again tightening restrictions and reinstituting lock down measures.
The virus is known to invade human cells through the ACE2 receptor-driven pathway, primarily impacting the respiratory tract.
While the number of study participants was too small to extrapolate for the whole population, the authors said they were encouraged.
Response to the COVID-19 pandemic has been hindered by lack of an effective antiviral therapy.
The U.S. sentinel surveillance program is a project which monitors for antibiotic-resistant gonorrhea.
Influenza and pneumonia, though rare, occurred at roughly the same rate in both the high-dose and standard-dose vaccine groups.
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.
A universal flu vaccine is also another step closer, according to researchers at Mount Sinai.
The findings are consistent with the hypothesis that bats are the viral origin and reservoir species.